Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI107877

The Secondary Structure of Human Hageman Factor (Factor XII) and its Alteration by Activating Agents

Carl R. McMillin, Hidehiko Saito, Oscar D. Ratnoff, and Alan G. Walton

Department of Macromolecular Science, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106

Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106

University Hospitals of Cleveland, Cleveland, Ohio 44106

Find articles by McMillin, C. in: PubMed | Google Scholar

Department of Macromolecular Science, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106

Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106

University Hospitals of Cleveland, Cleveland, Ohio 44106

Find articles by Saito, H. in: PubMed | Google Scholar

Department of Macromolecular Science, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106

Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106

University Hospitals of Cleveland, Cleveland, Ohio 44106

Find articles by Ratnoff, O. in: PubMed | Google Scholar

Department of Macromolecular Science, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106

Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106

University Hospitals of Cleveland, Cleveland, Ohio 44106

Find articles by Walton, A. in: PubMed | Google Scholar

Published December 1, 1974 - More info

Published in Volume 54, Issue 6 on December 1, 1974
J Clin Invest. 1974;54(6):1312–1322. https://doi.org/10.1172/JCI107877.
© 1974 The American Society for Clinical Investigation
Published December 1, 1974 - Version history
View PDF
Abstract

Hageman factor (factor XII) is activated by exposure to surfaces such as glass or by solutions of certain compounds, notably ellagic acid. Changes in the structure of Hageman factor accompanying activation have been examined in this study by circular dichroism spectroscopy. The spectrum of unactivated Hageman factor in aqueous solutions suggests that its conformation is mainly aperiodic. Various perturbants altered the conformation of Hageman factor in differing ways, demonstrating the sensitivity of Hageman factor to its environment.

After activation of Hageman factor with solutions of ellagic acid, a negative trough appeared in the region of the circular dichroism spectrum commonly assigned to tyrosine residues, along with other minor changes in the peptide spectral region. Some of these changes are similar to changes that occurred upon partial neutralization of the basic residues at alkali pH. Activation of Hageman factor by adsorption to quartz surfaces (in an aqueous environment) also produced changes similar to those in the ellagic acid-activated Hageman factor, including the negative ellipticity in the tyrosine region.

These observations suggest that the activation process may be related to a change in status of some of the basic amino acid residues, coupled with a specific change in the environment of some tyrosine residues. The importance of these changes during the activation process remains to be determined. The sensitivity of Hageman factor to its environment is consistent with the view that the initiation of clotting by exposure of plasma to appropriate agents is brought about by alterations in the conformation of Hageman factor that occur in the apparent absence of Fletcher factor or other recognized clotting factors.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1312
page 1312
icon of scanned page 1313
page 1313
icon of scanned page 1314
page 1314
icon of scanned page 1315
page 1315
icon of scanned page 1316
page 1316
icon of scanned page 1317
page 1317
icon of scanned page 1318
page 1318
icon of scanned page 1319
page 1319
icon of scanned page 1320
page 1320
icon of scanned page 1321
page 1321
icon of scanned page 1322
page 1322
Version history
  • Version 1 (December 1, 1974): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts